This study will test the ability of a personalized blood test to determine which head and neck cancer patients will have a recurrence after treatment.
Newly diagnosed AJCC 8th edition Stage III-IVB mucosal SCC of the head and neck, which includes tumors arising from the oral cavity, nasal cavity, paranasal sinuses, nasopharynx, oropharynx, hypopharynx, and larynx.
Available tissue for tumor-informed ctDNA panel creation.
Definitive treatment with standard of care surgery or chemoradiotherapy is planned to be administered at Massachusetts Eye and Ear Institute (MEEI) or within the Massachusetts General Hospital (MGH) Cancer Center (including but not limited to the Boston, Danvers, and Newton-Wellesley locations).
Patients <18 years of age
Patients receiving non-standard of care therapy as determined by the clinical investigator
Participants who have undergone prior surgical resection, excisional biopsy, radiation, and/or chemotherapy for the treatment of HNSCC. Prior incisional biopsies are permitted. Discrepant cases will be reviewed by study PI.
Participants who are receiving any investigational agents at the time of enrollment.
Massachusetts Eye and Ear Infirmary
Lead sponsor
Massachusetts General Hospital
Sponsor institution
Haystack Oncology, Inc.
Collaborator